THRX — Theseus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $181.72m
- -$23.40m
Brief: Theseus Pharmaceuticals Q2 EPS USD -0.34
Theseus Pharmaceuticals falls on ending study on stomach cancer drug
Theseus Pharma down on discontinuing study of stomach cancer drug
Brief: Theseus Pharmaceuticals To Discontinue Enrollment In Phase 1/2 Study And Terminate Development Of The-630 In Patients With Gist
Brief: Theseus Pharmaceuticals Reports Initial Dose Escalation Data From Ongoing Phase 1/2 Trial Of The-630 In Patients With Advanced GIST
Brief: Theseus Pharmaceuticals Reports Q1 2023 Financial Results, Business Highlights
Brief: Theseus Pharmaceuticals Q1 net loss USD 14.586 million
Brief: Theseus Pharma Announces Business Highlights And Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Theseus Pharmaceuticals Announces Preliminary Estimate Of Cash and Cash Equivalents Of About $211.8 Mln
Brief: Theseus Pharmaceuticals Announces BCR-ABL as Target for Third Development Program
Brief: Theseus Pharmaceuticals Inc Files For Potential Mixed Shelf Of Up To $300 Million - Filing
Brief: Theseus Pharmaceuticals Announces Business And Pipeline Highlights And Reports Third Quarter 2022 Financial Results
Brief: Theseus Pharmaceuticals Presents Preclinical Data Characterizing The-349, Its Fourth-Generation Egfr Inhibitor In Development For Nsclc, At The 34Th Eortc-Nci-Aacr Symposium
Brief: Theseus Pharmaceuticals Appoints Steven Stein, M.D. To Board Of Directors
Brief: Theseus Pharmaceuticals Nominates The-349, A Fourth-Generation EGFR Inhibitor Development Candidate In Non-Small Cell Lung Cancer
Brief: Theseus Pharmaceuticals reports Q2 results
Brief: Theseus Pharmaceuticals Inc - On May 17, Board Expanded Size Of Board From Five To Six Directors
Brief: Theseus Pharmaceuticals Appoints Don Hayden To Board Of Directors
Brief: Theseus Pharmaceuticals Announces Business Highlights And Reports First Quarter 2022 Financial Results